(Q39780949)

14 September 2017

title

A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease (English)

1 reference

14 September 2017

0 references

Richard Y Zhang

1

1 reference

14 September 2017

Andrew C Leon

series ordinal

2

1 reference

14 September 2017

Christy Chuang-Stein

series ordinal

3

1 reference

14 September 2017

Steven J Romano

series ordinal

4

1 reference

14 September 2017

publication date

1 February 2011

1 reference

14 September 2017

1 reference

14 September 2017

volume

8

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

5-14

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Modelling mini mental state examination changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

The delayed-start study design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

FDA: evidentiary standards for drug development and approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Design and analysis of two-period studies of potentially disease-modifying treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Disease-modifying trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510392255

21 January 2018

Identifiers

DOI

10.1177/1740774510392255

1 reference

14 September 2017

1 reference